Firms struggling over hand sanitiser packaging material
The huge increase in demand for hand sanitisers since the outbreak of the coronavirus pandemic has seen companies hard-pressed to cope with the logistics.
List view / Grid view
The huge increase in demand for hand sanitisers since the outbreak of the coronavirus pandemic has seen companies hard-pressed to cope with the logistics.
Exploring Operation Warp Speed, the Trump Administration’s program to expedite R&D, manufacturing and distribution of medical countermeasures for COVID-19.
Research suggests almost 70 percent of global clinical trials have been disrupted by enrolment suspensions caused by the COVID-19 pandemic.
According to findings, the majority of CMOs in Italy are found in the locations hit worst by COVID-19, meaning the pharma supply chain has been greatly impacted.
A group of researchers has found that IFN-α2b therapy reduced blood levels of IL-6 and C-reactive protein, two inflammatory proteins found in COVID-19 patients.
A group of four CROs at BioCity Nottingham have joined forces to collectively work on the research of COVID-19 therapies.
A survey has revealed that the majority of adults in the UK believe governments need to work together to develop COVID-19 vaccines and treatments, which if effective, should be used worldwide.
A double-blind clinical trial has begun in the US to study hydroxychloroquine and azithromycin treatment in patients with COVID-19.
Following the recall of Spartan Bioscience's COVID-19 test by Health Canada, a report suggests this demonstrates the challenges associated with rapid approval.
A new software has been developed, made to help find and enrol COVID-19 positive patients to accelerate clinical trials for new drugs and vaccines.
The US FDA has given Fast Track Designation to Moderna's mRNA vaccine candidate, mRNA-1273, designed to protect against COVID-19.
A new report has highlighted that the early successes of Avigan (favipiravir) and DAS181 do not guarantee their efficacy against COVID-19.
According to a new agreement between Mylan and Gilead, the former has the rights to manufacture and distribute remdesivir in 127 countries, a drug being tested to combat COVID-19.
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
Experts from the US National Institutes of Health have written a commentary to promote a collaborative approach for the testing, scale-up and distribution of COVID-19 vaccine candidates.